LC-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Inhibition of these transporters leads to an increase in serotonergic and noradrenergic signalling at postsynaptic receptors. Each drug blocks SERT versus NET differently, which is why there are differences in side effect profiles and therapeutic effects.
== Regulation == Bassoon protein and pLG72, are the current known proteins to physically interact and modulate human DAAO. plG72 is the product of the primate-specific G72 gene, and higher levels of both were observed in schizophrenia patients. Interaction of plG72 with hDAAO was observed to cause a time-dependent inactivation with the oxidase. This is believed to be caused by plG72 binding limiting the amount of the enzyme that is catalytically competent, and can be negated by the cofactor or any active-site ligands. The plG72 structure is not fully determined so the specific physical interaction with hDAAO is not completely understood as well. Experiments with the basson protein and hDAAO has resulted with a decrease in enzymatic activity similar to plG72. Researchers suspect the bassoon protein prevents D-serine depletion particularly in the presynaptic neuron. Additionally, researchers focused on compounds that could act as hDAAO inhibitors. Over 500 different compounds have been observed in vitro/in vivo to act as inhibitors on the oxidase and most of them do by competitive inhibition. All of these compounds have two similar, main portions. The first portion is the planar portion which interacts with the active site of hDAAO. The planar site’s chemical structure is formed by one or two fused rings and must have a negatively charged carboxylic group. The second portion is the substrate chain, which can participate in the active zone or entrance of the enzyme.
== Other foreign interventions == Other European Parliament corruption scandals involve foreign interventions. Green Party MEP Viola von Cramon-Taubadel said that Kazakhstan, Azerbaijan and Russia also "systematically purchased influence over an extended period". In 2025 foreign interventions by China were investigated.
Amifostine is an organic thiophosphate prodrug which is hydrolysed in vivo by alkaline phosphatase to the active cytoprotective thiol metabolite, WR-1065. The selective protection of non-malignant tissues is believed to be due to higher alkaline phosphatase activity, higher pH, and vascular permeation of normal tissues. Amifostine can be administered intravenously or subcutaneously after reconstitution with normal saline. Infusions lasting less than 15 minutes decrease the risk of adverse effects. The patient should be well-hydrated prior to administration.
== Lobbying == The company engages in lobbying in the United States. It also lobbies the Government of Ontario and House of Commons of Canada through Rubicon Strategy, a firm owned by Progressive Conservative Party of Ontario campaign manager Kory Teneycke. Pfizer lobbied various officials in the Government of British Columbia between April and November 2012, including then-premier Christy Clark, future premier John Horgan, future health minister Adrian Dix, and future deputy premier, minister of public safety and solicitor general Mike Farnworth. Notable lobbying organizations or think tanks to which the company has contributed include BIOTECanada, Bipartisan Policy Center, The Business Council, Business Council for the United Nations, Center on Budget and Policy Priorities, European Federation of Pharmaceutical Industries and Associations, Foundation for the National Institutes of Health, Global Health Council, Innovative Medicines Canada, International Federation of Pharmaceutical Manufacturers & Associations, National Health Council, Pharmaceutical Advertising Advisory Board, Pharmaceutical Research and Manufacturers of America, Reagan-Udall Foundation, U.S. Global Leadership Coalition, and World Economic Forum.
Sources: en.wikipedia.org
== In popular culture == King Naram-Sin is a character in the 2021 video game House of Ashes, with the main plot occurring in his personal temple. In the game, he is the self-proclaimed "God King" of Akkad, and is engaged in a war with the Gutians after being cursed by the god Enlil; whom he angered after the sacking of his temple. Naram-Sin was voiced and motion captured by Sami Karim. In the 2021 mobile gacha game Blue Archive, Volume F, the innermost chamber of the large floating quantum supercomputer known as the "Ark of Atra-Hasis" (itself a reference to the Akkadian myth) is named "Throne of Naram-Sin".
=== Dextran prodrug applications === These drug-polymer complexes have advantages such as longer drug half-life and improved targeted drug delivery. Dextran prodrugs have potential applications in the treatment of liver diseases, pulmonary diseases, colonic diseases, and cancer.
==== Probing pocket depth (PPD) ==== Pocket depth is the distance from the gingival margin to the base of the pocket. The position of the gingival margin can change due to swelling or recession, and vary with inflammation if force of probing, therefore, probing depth measurement alone is not recommended for assessment of changes in periodontal support over time.
Electroconvulsive therapy can differ in its application in three ways: electrode placement, frequency of treatments, and the electrical waveform of the stimulus. These three forms of application have significant differences in both adverse side effects and symptom remission. After treatment, drug therapy is usually continued, and some patients receive maintenance ECT. ECT appears to work in the short term via an anticonvulsant effect mostly in the frontal lobes, and longer term via neurotrophic effects primarily in the medial temporal lobe.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.